Recent Updates
Recently added Catalysts
EW Negative Sentiment Score: 25/100

Edwards Lifesciences Corporation Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Edwards Lifesciences Corporation Shareholders of Deadline in Securities Fraud Class Action Lawsuit

Key Takeaway: A securities class action lawsuit has been filed against Edwards Lifesciences Corporation, alleging that the company misrepresented the performance and growth potential of its Transcatheter Aortic Valve Replacement (TAVR) product. The lawsuit cites misleading statements and concealment of material facts about the TAVR platform during the specified class period. Investors are advised to consider their options, including becoming lead plaintiffs, before the upcoming deadline of December 13, 2024.

Market Sentiment Analysis

CONCERNS & RISKS

  • A securities fraud class action lawsuit has been filed against Edwards Lifesciences Corporation.
  • The lawsuit alleges that the company provided materially false and misleading statements about the growth of its TAVR product.
  • Defendants are accused of concealing adverse facts about the TAVR platform's true state.
  • Investors are reminded of a strict deadline to seek lead plaintiff status, highlighting urgency and potential losses.

Full Press Release Details

RADNOR, Pa., Dec. 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is December 13, 2024.
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com.
DEFENDANTS’ ALLEGED MISCONDUCT:
The complaint alleges that, throughout the Class Period, Defendants provided overwhelmingly positive statements to investors related to the growth of the company's core product, Transcatheter Aortic Valve Replacement ("TAVR"), while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Edwards’ TAVR platform. Specifically, Edwards’ claims and confidence relied far too heavily on their perceived ability to engage the claimed low-treatment-rate population of patients and an overestimation of the desire for hospitals and other care facilities to continue to utilize and otherwise commit resources to the TAVR procedures over newer, innovative treatment alternatives.
Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/hnxR1_RnFHI
THE LEAD PLAINTIFF PROCESS:
Edwards investors may, no later than December 13, 2024, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Edwards investors who have suffered significant losses to contact the firm directly to acquire more information.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
Kessler Topaz Meltzer & Check, LLP
280 King of Prussia Road
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What is the lawsuit against Edwards Lifesciences about?

The lawsuit alleges that Edwards provided misleading information about its TAVR platform during the class period.

When is the lead plaintiff deadline for the lawsuit?

The deadline for appointing a lead plaintiff is December 13, 2024.

How can Edwards investors who suffered losses get help?

Investors can contact Kessler Topaz Meltzer & Check, LLP for assistance.

What does being a lead plaintiff entail?

A lead plaintiff represents all class members in directing the litigation process.

Who can serve as lead plaintiff in this case?

Typically, the lead plaintiff is the investor with the largest financial interest and typicality.

Last updated: Dec 5, 2024